DUBLIN--(BUSINESS WIRE)--The "Global Sarcoidosis Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The sarcoidosis therapeutics market will register a CAGR of more than 4% by 2023.
Strategic alliances to gain traction in the market
Pharmaceutical companies are working together for the development of medications for the treatment of sarcoidosis. These alliances will enhance the R&D activities of new drugs for the management of sarcoidosis.
Rising awareness about sarcoidosis
The signs and symptoms of sarcoidosis are very broad, sometimes resemble the symptoms of other diseases. The increase in the number of organizations and institutes that create awareness about sarcoidosis among people and is expected to propel growth of the global sarcoidosis therapeutics market during the forecast period.
Side effects of available medicines
Although several off-label medications are available for the symptomatic treatment of sarcoidosis, the side effects associated with them are decreasing their preference.
Key Players
- Fresenius
- Horizon Pharma
- Johnson & Johnson Services
- Mallinckrodt
- Pfizer
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY PRODUCT
- Comparison by product
- Corticosteroids - Market size and forecast 2018-2023
- Other therapeutics - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Fresenius
- Horizon Pharma
- Johnson & Johnson Services
- Mallinckrodt
- Pfizer
For more information about this report visit https://www.researchandmarkets.com/research/v5sct7/global?w=4